In This Article:
Truist lowered the firm’s price target on Regeneron (REGN) to $940 from $975 but keeps a Buy rating on the shares. The firm is reducing its expected Eylea sales given the company’s near-term outlook, though while near-term investor focus remains on the Eylea tail,…